LIDDS Beheer

Beheer criteriumcontroles 0/4

We currently do not have sufficient information about the CEO.

Belangrijke informatie

Mats Wiking

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.9yrs
Gemiddelde ambtstermijn bestuur	less than a year

Recente managementupdates

Recent updates

CEO

Mats Wiking (55 yo)

less than a year

Tenure

Mats Wiking serves as the CEO, Head of IR and CFO of LIDDS AB (publ) since September 01, 2024. Mats Wiking has long financial experience as Finance Director, Controller and Business Developer from both sma...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Mats Wiking	CEO, CFO & Head of IR	less than a year	geen gegevens	geen gegevens
Monica Wallter	Senior Advisor	3.6yrs	SEK 1.87m	geen gegevens
Kia Bengtsson	Head of Clinical Development	2.1yrs	geen gegevens	geen gegevens
Roger Belusa	Chief Medical Officer	1.7yrs	geen gegevens	geen gegevens

1.9yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: LIDDS's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Stefan Rehnmark	Independent Director	less than a year	geen gegevens	4.86% SEK 1.1m
Torbjörn Browall	Director	less than a year	geen gegevens	3.48% SEK 760.0k
Lars-Inge Sjoqvist	Director	less than a year	geen gegevens	geen gegevens
Daniel Lifveredson	Chairman	less than a year	SEK 66.00k	20.28% SEK 4.4m
Bengt Viterius	Deputy Board Member	less than a year	geen gegevens	geen gegevens

0.8yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: LIDDS's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.

LIDDS Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

LIDDS AB (publ) Announces CFO Changes, Effective 1 September 2024

LIDDS AB (publ), Annual General Meeting, May 27, 2024

LIDDS AB (publ) Approves Board Elections

Lidds AB (Publ) Announces Resignation of Daniel Lifveredson from Board of Directors

LIDDS AB (publ) Announces CEO Changes

High number of new directors

Recent updates

LIDDS AB (publ) to Report Fiscal Year 2024 Results on Feb 20, 2025

LIDDS AB (publ) to Report Nine Months, 2024 Results on Nov 21, 2024

LIDDS AB (publ) to Report First Half, 2024 Results on Aug 28, 2024

LIDDS AB (publ) Announces CFO Changes, Effective 1 September 2024

New major risk - Shareholder dilution

LIDDS AB (publ), Annual General Meeting, May 27, 2024

LIDDS AB (publ) (OM:LIDDS) completed the acquisition of Noviga Research AB.

LIDDS AB (publ) (OM:LIDDS) signed an agreement to acquire Noviga Research AB.

LIDDS AB (publ) (OM:LIDDS) signed an agreement to acquire Noviga Research AB.

LIDDS AB (publ) Approves Board Elections

LIDDS AB (publ) to Report Fiscal Year 2023 Final Results on Apr 23, 2024

Lidds AB (Publ) Announces Resignation of Daniel Lifveredson from Board of Directors

LIDDS AB (publ) to Report Q1, 2024 Results on May 15, 2024

First half 2023 earnings released: kr0.29 loss per share (vs kr0.58 loss in 1H 2022)

LIDDS AB (publ) Announces CEO Changes

New major risk - Financial position

First quarter 2023 earnings released: kr0.29 loss per share (vs kr0.29 loss in 1Q 2022)

Full year 2022 earnings released: kr1.07 loss per share (vs kr1.16 loss in FY 2021)

LIDDS AB (publ) to Report Fiscal Year 2022 Results on Apr 25, 2023

Third quarter 2022 earnings released: kr0.23 loss per share (vs kr0.26 loss in 3Q 2021)

Second quarter 2022 earnings released: kr0.29 loss per share (vs kr0.32 loss in 2Q 2021)

LIDDS AB (publ) to Report Fiscal Year 2022 Results on Feb 24, 2023

High number of new directors

LIDDS AB (publ) Announces CEO Changes

LIDDS Patent Covering the NanoZolid® Production Process Granted in Israel

LIDDS AB (publ) Announces Board Changes

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

First quarter 2022 earnings: EPS and revenues miss analyst expectations

LIDDS AB (publ) to Report Q2, 2022 Results on Aug 25, 2022

No independent directors

LIDDS AB (publ) announced that it expects to receive SEK 40.8 million in funding from Nice & Green SA

LIDDS AB Next Step with Nanozolid® Formulated Docetaxel

LIDDS AB Announces Positive Topline Results from the Phase I Dose-Escalating Study of NanoZolid-Formulated Docetaxel

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

Will LIDDS (STO:LIDDS) Spend Its Cash Wisely?

Here's Why We're Not Too Worried About LIDDS' (STO:LIDDS) Cash Burn Situation

Director recently bought kr159k worth of stock

LIDDS AB (publ) Enters R&D Agreement with Potential Exclusive, Global Product License Option

New 90-day low: kr13.50

LIDDS AB (publ) and Pharmidea Signs Manufacturing Agreement

LIDDS Files Patent Application for Method to Treat Brain Cancer with Intratumoral Depot Injections

LIDDS AB (publ) Provides Update on Chinese Conditional Market Approval (CMA) for Liproca® Depot

LIDDS AB (publ) Announces Management Changes, Effective April 19, 2021

We're Not Very Worried About LIDDS' (STO:LIDDS) Cash Burn Rate

New 90-day low: kr13.00

New 90-day low: kr13.10

LIDDS AB (publ) Announces Data on Liproca Depot from Open Label Extension Study

New 90-day high: kr16.15

LIDDS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 37.083996 million.

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd